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Pathogenesis-Based Therapy Reverses Cutaneous
Abnormalities in an Inherited Disorder of Distal
Cholesterol Metabolism
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Debra Crumrine4, Michel van Geel2, Antonio Noda Cabrera3 and Peter M. Elias4
Identification of the underlying genetic, cellular, and biochemical basis of lipid metabolic disorders provides an
opportunity to deploy corrective, mechanism-targeted, topical therapy. We assessed this therapeutic approach
in two patients with Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD)
syndrome, an X-linked dominant disorder of distal cholesterol metabolism. On the basis of the putative
pathogenic role of both pathway-product deficiency of cholesterol and accumulation of toxic metabolic
intermediates, we assessed the efficacy of combined therapy with lovastatin and cholesterol. We also evaluated
the basis for the poorly understood, unique lateralization of the cutaneous and bone malformations of CHILD
syndrome by analyzing gene activation in abnormal and unaffected skin. Ultrastructural analysis of affected skin
showed evidence of both cholesterol depletion and toxic metabolic accumulation. Topical treatment with
lovastatin/cholesterol (but not cholesterol alone) virtually cleared skin lesions by 3 months, accompanied by
histological and ultrastructural normalization of epidermal structure and lipid secretion. The unusual
lateralization of abnormalities in CHILD syndrome reflects selective clearance of keratinocytes and fibroblasts
that express the mutant allele from the unaffected side. These findings validate pathogenesis-based therapy that
provides the deficient end product and prevents accumulation of toxic metabolites, an approach of potential
utility for other syndromic lipid metabolic disorders.
Journal of Investigative Dermatology (2011) 131, 2242–2248; doi:10.1038/jid.2011.189; published online 14 July 2011
INTRODUCTION
The ichthyoses are a group of inherited scaling skin disorders
of diverse etiologies (Oji et al., 2010), which share a perme-
ability barrier abnormality that parallels the severity of the
clinical phenotype (review in Moskowitz et al., 2004;
Schmuth et al., 2007; Elias et al., 2008). Current treatment
of the ichthyoses remains symptomatic and largely directed
toward reducing the scaling component. This approach is
often ineffective, may be accompanied by toxicity (e.g., with
systemic retinoids), and is intuitively counterproductive, as
the hyperkeratosis and hyperplasia likely reflect an epidermal
homeostatic response to re-establishing a competent barrier
(Elias et al., 2010). Use of recombinant protein replacement
or gene therapy for genodermatoses remains remote, because
of the (i) widespread nature of the cutaneous phenotype;
(ii) difficulties in transcutaneous drug delivery; (iii) discomfort
of injections needed to bypass the largely impenetrable
epidermal barrier; (iv) enormous costs of the required
‘‘designer approach’’; and (v) uncertain long-term risks of
viral transduction.
Recent advances in our understanding of the underlying
genetic, cellular, and biochemical basis of many forms of
ichthyosis (Elias et al., 2010) present an alternative, intriguing
opportunity to initiate pathway- or mechanism-based therapy
for many of these disorders. In syndromic lipid metabolic
disorders, the cutaneous and extracutaneous manifestations
often reflect not only deficiency of pathway product (i.e.,
cholesterol, free fatty acids, or ceramides), but also accumu-
lation of toxic pathway metabolites (Holleran et al., 1994;
Zettersten et al., 1998; Kelley and Herman, 2001; Cooper
et al., 2003; Elias et al., 2008; Rizzo et al., 2010). In inherited
disorders of distal cholesterol metabolism, attempts are
underway to treat extracutaneous components by oral
coadministration of cholesterol and/or statins (Haas et al.,
2001; Chan et al., 2009; Szabo et al., 2010). Nevertheless,
this approach will inevitably be hampered by first-pass
hepatic metabolism of statins, as well as intrahepatic
incorporation of oral cholesterol into lipoprotein particles,
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which are unable to traverse the blood–brain barrier or access
peripheral tissues without low-density lipoprotein, such as
the epidermis (Ponec et al., 1992).
We hypothesized that topical application of these agents
could bypass hepatic first-pass metabolism, allowing direct
access not only to the skin but perhaps to extracutaneous
tissues as well. If validated, such topical pathogenesis
(pathway)-based therapy would show substantial inherent
advantages, including (i) disease-targeted and mecha-
nism-based specificity; (ii) inherent safety; (iii) relatively low
cost, in comparison with small molecule, recombinant
protein, or gene therapy; and (iv) exploitation of the ready
accessibility and visibility of the skin to assess therapeutic
efficacy and safety.
We have now validated this therapeutic approach in two
unrelated patients with a syndromic disorder of distal
cholesterol metabolism (Congenital Hemidysplasia with
Ichthyosiform erythroderma and Limb Defects, CHILD
syndrome, OMIM #308050), which includes a notoriously
unresponsive ichthyosis. CHILD syndrome is an X-linked
dominant disorder caused by mutations in NAD(P)H steroid
dehydrogenase-like (NSDHL) gene, which encodes a mem-
ber of the enzyme complex that removes the C-4 methyl
group from lanosterol (Figure 1; Grange et al., 2000; Kelley
and Herman, 2001). Most affected individuals are female, as
the disorder is largely embryonic lethal in males. Clinical
manifestations range from localized skin disease (‘‘CHILD
nevus’’) to extensive limb malformations, which entirely or
largely localize to one side of the body, often with a sharp
midline demarcation (lateralization; Happle, 2006). More
limited skin lesions may follow one or more lines of
Blaschko, a recognized pattern of ectodermal development
(Sun and Tsao, 2008). The basis for the unique lateralization
in CHILD syndrome is unknown.
We report here that the skin lesions in both patients
responded significantly to topical coapplication of chole-
sterol and lovastatin (but not to cholesterol alone). The
striking improvement through topical delivery supports
the use of such topical, pathogenesis-based therapy for
cutaneous, and possibly extracutaneous, manifestations of
syndromic disorders of lipid metabolism.
RESULTS
Description of cases
Patient 1: A 13-year-old girl was born with marked soft tissue
and bone deformities, including digit-like protrusions on the
distal aspects of the markedly reduced left upper and lower
extremities. Her skin displayed ichthyosiform, erythrodermic
plaques on the left side of her body. At 3 years of age, her
rudimentary left lower leg was amputated to allow fitting of a
prosthesis. However, her ichthyosis involved the entire left
thigh and stump (Figure 2a), preventing her from wearing the
prosthesis because of persistent skin breakdown. She showed
no cutaneous or bone defects of the right side. The patient
was treated with petrolatum-based emollients without
benefit. She neither tolerated nor improved with topical
applications of keratolytics, retinoids, corticosteroids, or
calcineurin inhibitors. At 9 years of age, she developed an
enlarging, pendulous tumor of the vulva and left inner thigh.
Tumor sections histologically revealed verruciform xantho-
matosis, which was debulked at 12 years of age. DNA
sequencing from blood leukocytes showed a c.248G4A
transition in exon 3 of one allele of NSHDL at Xq28,
predicting the substitution p.Gly83Asp (G83D) and verifying
the diagnosis of CHILD syndrome.
Patient 2: A 22-year-old woman was born with a severely
malformed right lower extremity, necessitating amputation
during early childhood, and malformations of the right hand
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Figure 1. The cholesterol biosynthetic pathway. 3-Hydroxy-3-methyl-
glutaryl-coenzyme A reductase (HGMCR) is a rate-limiting step early in
the cholesterol biosynthetic pathway, which is inhibited by statins.
CHILD (Congenital Hemidysplasia with Ichthyosiform erythroderma and
Limb Defects) syndrome results from mutations in NAD(P)H steroid
dehydrogenase-like (NSDHL) gene, which prevent the post-lanosterol
generation of cholesterol, potentially leading to pathway-product deficiency
in addition to metabolite accumulation. Conradi–Hu¨nermann–Happle
syndrome is due to mutations in a gene encoding emopamil-binding protein
(EBP), which functions distal to NSDHL in cholesterol biosynthesis.
Baseline
Baseline
Baseline6 Weeks
8 Weeks
8 Weeks 1 Year6 Months
Figure 2. Clinical and histological improvement with topical applications of
lovastatin/cholesterol. (a) Treated skin of Patient #1. (b) Treated skin of
Patient #2. (c) Histopathological evaluation of lesional skin of Patient #2
at baseline (left) showed marked epidermal acanthosis with psoriasiform
hyperplasia. The granular layer was absent, and the stratum corneum showed
parakeratosis and retention hyperkeratosis. Bar¼ 25mm. By B3 months after
treatment initiation (right), the epidermis was of normal thickness with regular
orthokeratinization and a normal granular layer. Bar¼7 mm.
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with nail dystrophy. During the first few years of life, she
developed inflamed, thickened skin on the dorsal aspect of
the right hand that gradually extended to the right axilla
(Figure 2b). She had no abnormalities on the left side of her
body, except for a small, scaling plaque between the left third
and fourth fingers. The patient also had neurosensory
deafness of the right ear, and severe lumbar scoliosis. She
was treated for 17 years with topical emollients, steroid
ointments, or cryotherapy, without significant improvement.
DNA sequencing from blood leukocytes showed a nonsense
mutation in exon 4 on one allele of the NSDHL gene
(c.317C4A; p.S106X), verifying the diagnosis of CHILD
syndrome. Hphl digestion of the PCR fragment confirmed the
predicted abnormal restriction pattern, which was not
observed in controls (courtesy of Professor K. Grzeschik,
Marburg, Germany).
Efficacy and mechanism of pathogenesis (pathway)-based
therapy
Clinical observations. We first addressed the possibility that
skin lesions in CHILD syndrome primarily reflect cholesterol
(pathway end product) deficiency alone, but found no
clinical improvement after 3 months of treatment with twice
daily topical 10% cholesterol in hydrophilic ointment.
We next considered the possibility (supported by ultrastruc-
tural studies described below) that the cutaneous phenotype
reflects both cholesterol deficiency and accumulation of
toxic sterol metabolites. Lesional skin of both patients was
treated twice daily with 2% lovastatin/2% cholesterol lotion.
Decreased inflammation, skin thickening, and scaling was
noted as early as 4–6 weeks in both patients, and the severity
scores decreased by 72% (patient 1) and 79% (patient 2) by
3 months. By 6 months, treated skin largely normalized,
but did not grow hair (Figure 2a). Patient #1, now more than
1 year on therapy, uses the medication twice weekly with
good control and is able to wear her prosthesis. Patient #2 has
been treated for more than 17 months, now once to twice
weekly, and shows residual hypopigmentation without
inflammation or scaling (Figure 2b). She has improved digital
mobility, but little improvement in onychodystrophy, likely
reflecting the inability of the compound to penetrate the nail.
Patient #2 discontinued therapy for 15 days while on
vacation, without relapse. In both patients, the compounded
lotion has been well tolerated. Laboratory testing 6 months
after initiation of dual therapy revealed no changes in blood
counts, hepatic function, creatinine, or serum lipids.
Light and electron microscopic alterations. Baseline biopsy
sections of skin lesions from both patients before treatment
showed marked hyperkeratosis and acanthosis with the
absence of the granular layer and dermal foam cells (Figure
2c, left). Ultrastructural assessment of these biopsies showed
severe alterations in the epidermal lamellar body (lipid)
secretory system. Individual organelles displayed few internal
lamellae, which often fused prematurely into intracellular,
multivesicular bodies that were incompletely secreted
(Figure 3a–c). Partial failure of organelle secretion correlated
with the presence of entombed organelle contents within
corneocytes (Figure 3c), and retention of acid lipase, an
organelle content marker, within corneocytes (Figure 4a).
Finally, and as a result of impaired secretion, the stratum
corneum extracellular matrix displayed a paucity of secreted
lamellar material, interspersed with abundant non-lamellar
vesicles (Figure 3c; open arrows). In contrast, biopsy sections
after 3 months of treatment showed a largely normal
epidermis, with a prominent granular layer and orthoker-
atotic scale by light microscopy (Figure 2c, right). Moreover,
ultrastructural analysis showed nearly complete resolution of
the structural abnormalities in the lamellar body secretory
system, and normalization of secretion in both patients
(Figures 3d, e and 4b).
A subclinical phenotype persists in clinically unaffected sites
Pretreatment biopsies were also obtained from a contral-
ateral, ‘‘unaffected’’ skin site in Patient #1. Although no
visible ichthyosiform features could be appreciated either
clinically or by light microscopy, ultrastructural images
displayed mild abnormalities in lamellar body internal
contents and lamellar bilayer organization, with the presence
of lamellar/non-lamellar phase separation but not disordered
secretion (Figure 5a–c). These findings, although far less
prominent than images from clinically affected sites and
without evidence of cytotoxicity, suggested that residual
abnormalities persist in ‘‘uninvolved’’ skin, prompting
examination of gene expression in these affected versus
‘‘unaffected’’ contralateral sites.
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Figure 3. Ultrastructural normalization from pathogenesis-based therapy in
CHILD syndrome. (a, b) Pretreatment biopsies show prominent abnormalities
in epidermal lamellar body morphology (asterisks) and secretion in the
stratum granulosum (SG). (c) Impaired secretion results in entombment of
unsecreted organelle contents within stratum corneocytes (SC, solid arrows)
and reduced lamellar material in the SC interstices (open arrows), with
massive distended foci of non-lamellar/amorphous material between
corneocytes (asterisks). Post-treatment biopsies (d, e) show substantial
improvement in lamellar body contents (e) and secretion, but some foci of
non-lamellar material persist (d, open arrows). a, b, and e: Osmium tetroxide
post-fixation; c and d: ruthenium tetroxide post-fixation. Bars: panels
a¼0.2 mm, b¼0.5 mm, c¼0.2 mm, d and e¼ 0.1 mm. CHILD, Congenital
Hemidysplasia with Ichthyosiform erythroderma and Limb Defects.
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Genetic basis for clinically normal skin in CHILD syndrome
X-inactivation studies on peripheral blood leukocytes showed
preferential inactivation of one allele (89þ2% of normal
allele), consistent with skewing of X-inactivation. Genomic
DNA sequencing from both sets of keratinocytes showed
equal representation of both alleles (Figure 6). However,
reverse transcription–PCR on complementary DNA (cDNA)
from keratinocytes and fibroblasts isolated from the affected
and clinically unaffected side in Patient #1 demonstrated
exclusive expression of the mutant allele by affected cultured
keratinocytes, whereas unaffected keratinocytes solely
expressed the wild-type allele (Figure 6). Only the normal
allele was expressed by unaffected fibroblasts, but fibroblasts
from the clinically affected area expressed an approximately
even distribution of normal and mutant alleles.
DISCUSSION
Discovery of genetic changes underlying thousands of
disorders has increased our understanding of normal cell
function, as well as the cellular and molecular abnormalities
that lead to disease phenotypes. In addition, we can now
consider the possibility of pathogenesis-based therapy.
To consider the feasibility of pathogenesis-based therapy,
we chose CHILD syndrome, an X-linked dominant disorder
of distal cholesterol synthesis, as our disease prototype.
We show here that topical application of the deficient
pathway end product (cholesterol) is ineffective, but prevent-
ing the accumulation of toxic metabolites (with a statin) and
replenishing end product corrects the cutaneous phenotype.
The lack of efficacy of cholesterol alone is not due to the
absence of low-density lipoprotein receptors in epidermis,
given that the keratinocyte is able to incorporate 7-nitro-
2,1,3-benzoxadiazole-labeled cholesterol (Man et al., 1993;
Mao-Qiang et al., 1995). However, the response to dual
therapy, rather than to monotherapy, probably reflects both
the sterol depletion and metabolite accumulation that result
from pathogenic mutations in enzymes of cholesterol
synthesis, including CHILD syndrome (Porter and Herman,
2011). Blockade of metabolite production alone, however, is
also insufficient. Indeed, normal mouse skin treated with
topical statins develops ichthyosiform changes (Feingold
et al., 1991; Menon et al., 1992a), reflecting the key role of
cholesterol in the epidermal barrier (Feingold et al., 1990;
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Figure 4. Ultrastructural cytochemical evidence of improved lamellar body
secretion in treated skin. (a) Pretreatment biopsy, assessed with an
ultrastructural marker of lamellar body contents, shows a large amount of
retained (unsecreted) lamellar body contents within stratum cornified cells
(SC, arrows). Open arrows indicate focal sites where organelle contents have
been secreted. (b) Post-treatment biopsy reveals that most enzyme activity has
been secreted (exteriorized; arrows). Osmium tetroxide post-fixation. Bars:
panels a¼ 0.5mm, b¼ 0.25mm.
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Figure 5. Clinically ‘‘unaffected’’ epidermis of CHILD syndrome shows
abnormalities of the lamellar body secretory system. Most of the lamellar
bodies in the stratum granulosum (SG) display abnormal internal contents (c,
asterisks). Lamellar body secretion is partially impaired, with entombment of
some organelles (a, open arrows) and retained acidic lipase activity in some
corneocytes, as shown by ultrastructural cytochemistry (b, open arrows). Also
note the inhomogeneous distribution of secreted enzyme activity (b, arrows).
Bars: panels a¼ 0.1mm, b¼ 0.5mm, and c¼0.2 mm. CHILD, Congenital
Hemidysplasia with Ichthyosiform erythroderma and Limb Defects.
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Elias, 2006). Statin-induced cholesterol deficiency leads to
decreased number and internal contents of epidermal
lamellar bodies, as well as altered lamellar bilayer architec-
ture, but no evidence of cytotoxicity (Feingold et al., 1990;
Menon et al., 1992a). In contrast, lesional skin from both
CHILD patients also displays much more severe alterations in
the lamellar body secretory system, indicative of metabolite-
induced toxicity. In fact, the mild ultrastructural changes in
clinically ‘‘unaffected’’ skin suggest cholesterol deficiency,
not accumulation of sterol precursors, and implicate toxic
metabolites in causing the ichthyosiform changes. Accumu-
lation of 4-methyl and 4,4-dimethyl sterol metabolites has
been shown in tissue samples from heterozygous mutant
female Bpa/Str mouse models of CHILD syndrome (Liu et al.,
1999), although near-normal levels of cholesterol and only
minimal elevations in sterol metabolites are found in serum in
these mice and in individuals with CHILD syndrome
(Hummel et al., 2003; Porter and Herman, 2011). This
discrepancy likely reflects the functional mosaicism and
skewed X-inactivation with widespread expression of the
normal allele outside of affected sites. Insertion of sterol
metabolites into cell membranes is known to induce
membrane functional abnormalities, as well as toxic effects
on oxysterol generation, altered hedgehog pathway signaling,
and accelerated degradation of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (Porter and Herman, 2011). The lack
of hair growth in affected areas, despite skin normalization
with lovastain/cholesterol treatment, provides evidence of
the important role of cholesterol and hedgehog pathway
signaling in hair follicle development (St-Jacques et al., 1998;
Chiang et al., 1999; Cunningham et al., 2009).
Our pathway-based therapeutic approach represents an
entirely new concept for the topical therapy of disorders of
distal cholesterol metabolism. Because it is pathway specific
rather than mutation specific, it has broad applicability
within this pathway. Cholesterol and lovastatin are generic
(i.e., relatively inexpensive), have a known safety profile, and
are lipid soluble, facilitating penetration across the stratum
corneum. The cholesterol/statin combination would likely be
useful for another, closely related disorder in this pathway
(Figure 1), Conradi–Hu¨nermann–Happle syndrome (CDPX2),
which similarly presents with bone malformations and
patterned ichthyotic skin lesions, but without lateralization
(Steijlen et al., 2007; Akiyama et al., 2009). In fact, topical
application of an end product plus an upstream pathway
inhibitor could well be useful for the many syndromic and
non-syndromic disorders of fatty acid and ceramide metabo-
lism. Metabolite-induced toxicity (with variable levels of
pathway product depletion) has been described in several
other syndromic, lipid metabolic disorders leading to
ichthyotic manifestations, including the relatively common
recessive X-linked ichthyosis, Sjo¨gren–Larsson syndrome,
neutral lipid storage disease (Chanarin–Dorfman syndrome),
type II (acute infantile neuronopathic) Gaucher disease, and
Refsum disease (review in Elias et al., 2008, 2010). In theory,
a comparable transdermal approach might also benefit the
extracutaneous manifestations of these syndromic disorders,
as the topical route would allow both the statin and
cholesterol to bypass hepatic first-pass metabolism.
We also addressed the distribution of CHILD
syndrome lesions through ultrastructural analysis and gene
inactivation studies. Given that the NSHDL gene resides on
Keratinocytes
Clinically unaffected
Fibroblasts
Clinically unaffected
Clinically affectedClinically affected
Blood
Keratinocytes—affected
Keratinocytes—unaffected
G/A
G/AG/A
G/A
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A
Figure 6. NSDHL gene expression. (a) Sequences of complementary DNA obtained from cultured keratinocytes and fibroblasts in unaffected (upper panel)
and affected (lower panel) areas of the skin. There is clear exclusive expression of the mutant c.248G4A allele in keratinocytes taken from affected skin,
whereas fibroblasts from this area express both the mutant and the normal allele. In the unaffected areas, only the wild type is found in keratinocytes as well
as fibroblasts. (b) Genomic DNA sequences obtained from peripheral blood leukocytes and unaffected and affected keratinocytes. All traces show the presence
of both wild-type and mutant alleles. Arrows point to the mutant residue. NSDHL, NAD(P)H steroid dehydrogenase-like gene.
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Xq28, its expression is subject to X-inactivation. Sequencing
of genomic DNA from cultured keratinocytes of the
‘‘unaffected’’ and ‘‘affected’’ sides both showed approxi-
mately equal amounts of mutant and normal gene. However,
sequencing of expressed DNA from keratinocytes from
lesional skin showed mutant NSDHL, whereas from kerati-
nocytes of clinically normal contralateral skin revealed only
the wild-type NSDHL. We speculate that the mild abnorm-
alities seen in ultrastructural analysis of ‘‘uninvolved skin’’, in
which cultured keratinocytes only express the normal allele,
could reflect a residual population of keratinocytes expres-
sing the mutant allele that is below our limit of detection
by sequencing (i.e., o5%). Interestingly, fibroblasts from the
clinically affected skin demonstrated both mutant and wild-
type NSDHL sequences, and fibroblasts from the clinically
normal side expressed only the normal genotype, accounting
for the concordance of the clinical and genotypic expression.
The exclusive expression of the normal allele in keratinocytes
and fibroblasts from the unaffected side explains the
favorable outcome of full-thickness grafts from the unaffected
to the affected side (Ko¨nig et al., 2010). Indeed, our patient
#1 had a full-thickness flap from the unaffected to the affected
side at the midline of the abdomen performed during
her procedure to debulk the verruciform xanthomatosis; this
flapped skin was clinically normal at 6 months after surgery
when the topical lovastatin/cholesterol therapy was initiated,
and remains clinically normal.
Whereas culture of keratinocytes can offer a potential
selective growth advantage of lesional or wild-type cells,
the strictly mutant or wild-type sequence, respectively, in
keratinocytes of lesional versus clinically normal skin
provides evidence that neither predominates in culture.
Although one might consider segregation of affected kerati-
nocytes as a mechanism for the observed expression patterns,
exclusive expression of the wild-type allele in both keratino-
cytes and fibroblasts on the unaffected side instead suggests
preferential clearance of affected cells. Similarly, the skewing
of X-inactivation in peripheral blood leukocytes is consistent
with overall depletion of affected cells (Sun and Tsao, 2008).
Preferential clearance of mutant cells postnatally has been
recently described in the liver and brain of the Bpa mouse
model of CHILD syndrome (Cunningham et al., 2009),
although it should be noted that the mouse model does not
show the lateralization of human CHILD syndrome. Although
the mechanism of this preferential clearance and resultant
lateralization remains unknown, its elucidation could
increase our understanding of spatial organization during
embryogenesis.
MATERIALS AND METHODS
Patient recruitment, clinical assessment, and genetic analysis
Following institutional approval of experiments, written informed
patient consent (and in the case of Patient 1 parental consent), and
adherence to the Declaration of Helsinki Principles, blood was
drawn from both patients for genetic analysis to identify the NSHDL
mutation. In addition, baseline photographs and biopsies of lesional
and contralateral non-lesional skin were obtained for routine
histology and electron microscopy. At both sites, three physicians
(three dermatologists in the Canary Islands, as well as a dermatol-
ogist and two pediatricians in the United States) each saw the
patients at each visit. All of them independently judged the progress
on a global basis, rating erythema, scaling, and thickening as 0 to
4þ . For mutation analysis, DNA was extracted from peripheral
blood leukocytes by salt precipitation. All coding exons (from three
to nine), including splice sites, were amplified by PCR (M13-tailed
primer sequences and PCR protocol on request). PCR products were
sequenced with universal M13-F and M13-R primers using the
BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA). The mutation nucleotide position is based on the
National Center for Biotechnology Information-reference sequence
BC007816.
Treatment protocol
Before application, only bland emollients were applied; these were
stopped for the trial and have not been restarted. A lovastatin 2%/
cholesterol 2% suspension in paraben-preserved water was applied
to the lesions of both patients twice daily for the first 6 months
(total applications limited to 30ml monthly), and then tapered to
maintain control. The compounded lotion was prepared with an
identical formulation at both sites by grinding lovastatin tablets (5 g),
combining with cholesterol powder (5 g), and mixing for at least
3minutes with an electronic mortar and pestle to obtain 240ml in
preserved water (http://www.markdrugs.com). Patients were
observed at 6–8 weeks, 3 months, and then at 3-month intervals
for clinical changes, as well as for potential adverse effects.
Assessment of ultrastructural pathology
After aldehyde prefixation, skin biopsies were processed for
hematoxylin and eosin staining, or post-fixed in either osmium
tetroxide or ruthenium tetroxide (to visualize lamellar bilayer
architecture), and embedded in Epoxy resin (Hou et al., 1991). An
additional piece was processed for ultrastructural cytochemistry
utilizing the lipid secretory marker, acidic lipase (Menon et al.,
1992b). Ultrathin sections were examined in a Zeiss electron
microscope (Carl Zeiss, Thornwood, NY), operated at 60 kV.
Investigation of gene inactivation
Skin samples for keratinocyte and fibroblast cultures were obtained
from lesional (left inguinal) and non-lesional (right inguinal) sites of
Patient #1. Epidermis and dermis were separated after overnight
incubation in Dispase (Roche Diagnostics, Indianapolis, IN) at 4 1C.
Keratinocyte and fibroblast suspensions, obtained by trypsinization,
were cultured (Rheinwald and Green, 1975). Genomic DNA
extracted from affected and unaffected keratinocytes was analyzed
for the c.248G4A mutation using the NSDHL exon 4 genomic PCR
primers as described above. Total RNA was isolated and purified
from the cultured cells with an RNeasy Kit (Qiagen, Valencia, CA),
and used to synthesize cDNA using a SuperScript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA). In brief, 1.5–2mg of total
RNA was mixed with random primers and dNTPs, with incubation
for 5minutes at 65 1C, followed by cooling. The cDNA was
synthesized by adding SuperScript and incubated at 50 1C for
50minutes, followed by incubation for 5minutes at 85 1C. After
removal of the remaining RNA with RNase H, 10–200 ng of the
cDNA was used for PCR reactions. Reverse transcription–PCR was
performed on the cDNA using primers in exons 4 and 5 flanking the
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mutation (NSDHL4cF 50-TGGATTCCTGGGGCAGCAC-30 and NSD
HL5cR 50-TTACTGGATGGTGGGGGTGAC-30, PCR-protocol on
request). PCR products were sequenced directly using the PCR
primers with the BigDye terminator v1.1 cycle sequencing kit
(Applied Biosystem). For analysis of X-inactivation, the polymorphic
CAG-repeat in exon 1 of the AR gene was PCR-amplified after
digestion with the methylation-sensitive enzymes, HhaI and HpaII
(Fearon et al., 1987).
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